Literature DB >> 31965263

Correction to: Expert statement on the ICU management of patients with thrombotic thrombocytopenic purpura.

Elie Azoulay1, Philippe R Bauer2, Eric Mariotte3, Lene Russell4, Paul Knoebl5, Ignacio Martin-Loeches6, Frédéric Pène7, Kathryn Puxty8, Pedro Povoa9,10,11, Andreas Barratt-Due12, Jose Garnacho-Montero13, Julia Wendon14, Laveena Munshi15, Dominique Benoit16, Michael von Bergwelt-Baildon17,18, Marco Maggiorini19, Paul Coppo20, Spero Cataland21, Agnès Veyradier22, Andry Van de Louw23.   

Abstract

The original version of this article unfortunately contained a mistake. The penultimate row of Table 4 shows INR > 1.5 which is incorrect. The correct figure is INR < 1.5. The authors apologize for the mistake. The correct table is given below.

Entities:  

Year:  2020        PMID: 31965263     DOI: 10.1007/s00134-019-05904-7

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  1 in total

1.  Caplacizumab for Acute Thrombotic Thrombocytopenic Purpura.

Authors:  Katherine V Katsivalis; Jamie Thomas
Journal:  J Adv Pract Oncol       Date:  2021-03-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.